

Sven GÃ¼nther

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1623430/publications.pdf>

Version: 2024-02-01

33
papers

2,936
citations

393982

19
h-index

476904

29
g-index

37
all docs

37
docs citations

37
times ranked

3472
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 36, 549-555.	3.1	582
2	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
3	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 97.	1.2	226
4	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 728-737.	3.1	213
5	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014, 44, 1275-1288.	3.1	201
6	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
7	Chemotherapy-Induced Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 356-371.	1.9	149
8	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. <i>Arthritis and Rheumatism</i> , 2012, 64, 2995-3005.	6.7	108
9	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. <i>Circulation</i> , 2015, 132, 834-847.	1.6	103
10	Pulmonary hypertension in lymphangiomyomatosis: characteristics in 20 patients. <i>European Respiratory Journal</i> , 2012, 40, 630-640.	3.1	80
11	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014, 44, 1627-1634.	3.1	80
12	Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. <i>Drug Discovery Today</i> , 2019, 24, 428-439.	3.2	74
13	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2012, 40, 75-83.	3.1	53
14	Prevalence of Self-Reported Pain, Joint Complaints and Knee or Hip Complaints in Adults Aged ≥ 40 Years: A Cross-Sectional Survey in Herne, Germany. <i>PLoS ONE</i> , 2013, 8, e60753.	1.1	53
15	Screening for pulmonary arterial hypertension in adults carrying a <i>BMP2</i> mutation. <i>European Respiratory Journal</i> , 2021, 58, 2004229.	3.1	50
16	Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , 2016, 47, 1436-1444.	3.1	44
17	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018, 196, 157-164.	1.4	42
18	Drugs induced pulmonary arterial hypertension. <i>Presse Medicale</i> , 2013, 42, e303-e310.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. <i>Chest</i> , 2013, 144, 1512-1520.	0.4	26
20	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4105.	1.8	21
21	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. <i>American Journal of Pathology</i> , 2019, 189, 1159-1175.	1.9	19
22	Endothelial Colony-Forming Cells from Idiopathic Pulmonary Fibrosis Patients Have a High Procoagulant Potential. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 694-699.	1.7	14
23	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. <i>European Respiratory Journal</i> , 2014, 43, 641-643.	3.1	11
24	Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. <i>PLoS ONE</i> , 2015, 10, e0134221.	1.1	10
25	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1469-1476.	0.8	10
26	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2015, 46, 1211-1214.	3.1	5
27	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016, 133, e592-3.	1.6	4
28	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2015, 184, 763-765.	0.8	3
29	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. <i>Journal of Clinical Monitoring and Computing</i> , 2017, 31, 903-910.	0.7	3
30	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
31	A study of magnesium deficiency in human and experimental pulmonary hypertension. <i>Magnesium Research</i> , 2012, 25, 21-27.	0.4	2
32	Acute Right Heart Failure in Pulmonary Hypertension. , 2014, , 261-275.		0
33	Overnight rostral fluid shift in group 1 pulmonary arterial hypertension. , 2015, , .		0